BioRestorative Therapies, Inc. — Director's Dealing 2023

Feb 27, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioRestorative Therapies, Inc. (BRTX)
CIK: 0001505497
Period of Report: 2023-02-18

Reporting Person: ALSTODT LANCE (Director, President, CEO, COB, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-18	Common Stock	F	374	$2.99	Disposed	186947	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option	$5.08	2031-03-18	Common Stock (293479)	293479	Direct
Stock Option	$5.08	2031-11-04	Common Stock (42059)	42059	Direct
Stock Option	$2.91	2033-02-17	Common Stock (106762)	106762	Direct

Footnotes

F1: Shares were withheld from vested stock grant to pay the associated withholding taxes.

F2: Includes 98,862 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.

F3: The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.

F4: The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.

F5: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 with the remaining 53,381 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested.